Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled trial of FF/UMEC/VI versus FF/VI in asthma
2016-001304-37Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in trough FEV1 at Week 24. Started Jul 2016; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-001304-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001304-37.